GlassScriptPhysician profile
Puja Myne
NPI 1215213160
$1,517.31
in general payments reported to CMS, 2019-2025
28 companies · $937 in 2025
The $937 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.93 · 2023: $45.04 · 2024: $521 · 2025: $937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,503.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $242.90 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $213.44 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $145.32 | 2024-2025 | |
| Pfizer INC. | $118.57 | 2024-2025 | |
| Glaxosmithkline, LLC. | $102.96 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Axsome Therapeutics, INC. | $74.77 | 2025 | Auvelity, Symbravo |
| Lilly USA, LLC | $64.99 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $63.47 | 2024-2025 | Veozah |
| Eisai INC. | $55.25 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.91 | 2025 | Xifaxan |
| Novo Nordisk INC | $44.79 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Dexcom, INC. | $42.72 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.85 | 2024-2025 | Jardiance |
| Corcept Therapeutics | $28.11 | 2025 | Korlym |
| Verity Pharmaceuticals INC. | $27.49 | 2025 | Tlando |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $23.03 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $18.00 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $16.93 | 2024 | Ajovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.62 | 2024 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $16.40 | 2025 | Zoryve |
| Merck Sharp & Dohme LLC | $16.11 | 2025 | Gardasil 9 |
| Phathom Pharmaceuticals, INC. | $15.41 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $15.28 | 2023 | Trintellix |
| Organon LLC | $15.19 | 2024 | |
| Tris Pharma INC | $14.76 | 2025 | Dyanavel Xr |
| Cipher Pharmaceuticals US LLC | $14.52 | 2025 | Spinosad, Natroba |
| Gilead Sciences, INC. | $13.93 | 2021 | |
| Exact Sciences Corporation | $13.59 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Puja Myne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.